Income Statement scPharmaceuticals Inc.

Stocks

SCPH

US8106481059

Pharmaceuticals

Delayed Nasdaq 00:00:00 07/10/2025 +04			5-day change	1st Jan Change
5.670 ^USD	-.--%		-.--%	-

07/10/25	MannKind Corporation completed the acquisition of scPharmaceuticals Inc..	CI
07/10/25	MannKind Completes Acquisition of scPharmaceuticals	MT

2009a2.pe5stU5IRV2cSUs9pEBNVaihZ65S53qZCzOMgox-NlQ.kpYD5ToeMRDzLRwQliwkYsbbSuVj1y79OAahx-suYw3kpiTRDXAOOdkFAg

Published financial data: SCPHARMACEUTICALS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Revenues	-	-	-	13.59M	36.33M
Total Revenues	-	-	-	13.59M	36.33M
Cost of Goods Sold, Total	-	-	-	3.81M	11.36M
Gross Profit	-	-	-	9.78M	24.97M
Selling General & Admin Expenses, Total	11.78M	9.78M	20.62M	53.37M	77.65M
R&D Expenses	18.15M	16.04M	15.53M	11.81M	12.1M
Other Operating Expenses, Total	29.93M	25.82M	36.16M	65.18M	89.75M
Operating Income	-29.93M	-25.82M	-36.16M	-55.4M	-64.78M
Interest Expense, Total	-2.59M	-2.58M	-3.3M	-8.12M	-7.57M
Interest And Investment Income	315K	49K	1.2M	5.1M	3.44M
Net Interest Expenses	-2.27M	-2.53M	-2.1M	-3.02M	-4.13M
Other Non Operating Income (Expenses)	-4K	315K	1.42M	3.6M	-129K
EBT, Excl. Unusual Items	-32.21M	-28.03M	-36.84M	-54.81M	-69.03M
Gain (Loss) On Sale Of Investments	-	-	-	-	120K
Other Unusual Items	-	-	-	-	-16.24M
EBT, Incl. Unusual Items	-32.21M	-28.03M	-36.84M	-54.81M	-85.15M
Earnings From Continuing Operations	-32.21M	-28.03M	-36.84M	-54.81M	-85.15M
Net Income to Company	-32.21M	-28.03M	-36.84M	-54.81M	-85.15M
Net Income - (IS)	-32.21M	-28.03M	-36.84M	-54.81M	-85.15M
Net Income to Common Incl Extra Items	-32.21M	-28.03M	-36.84M	-54.81M	-85.15M
Net Income to Common Excl. Extra Items	-32.21M	-28.03M	-36.84M	-54.81M	-85.15M
Per Share Items
Net EPS - Basic	-1.31	-1.02	-1.3	-1.42	-1.91
Basic EPS - Continuing Operations	-1.31	-1.02	-1.3	-1.42	-1.91
Basic Weighted Average Shares Outstanding	24.57M	27.35M	28.36M	38.51M	44.52M
Net EPS - Diluted	-1.31	-1.02	-1.3	-1.42	-1.91
Diluted EPS - Continuing Operations	-1.31	-1.02	-1.3	-1.42	-1.91
Diluted Weighted Average Shares Outstanding	24.57M	27.35M	28.36M	38.51M	44.52M
Normalized Basic EPS	-0.82	-0.64	-0.81	-0.89	-0.97
Normalized Diluted EPS	-0.82	-0.64	-0.81	-0.89	-0.97
Supplemental Items
EBITDA	-29.9M	-25.79M	-36.12M	-55.37M	-64.76M
EBITA	-29.93M	-25.82M	-36.16M	-55.4M	-64.78M
EBIT	-29.93M	-25.82M	-36.16M	-55.4M	-64.78M
EBITDAR	-29.46M	-25.34M	-35.62M	-54.66M	-64.36M
Normalized Net Income	-20.13M	-17.52M	-23.02M	-34.26M	-43.14M
Interest on Long-Term Debt	2.59M	-	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	11.78M	9.78M	20.62M	-	-
Research And Development Expense From Footnotes	18.15M	16.04M	15.53M	11.81M	12.1M
Net Rental Expense, Total	440K	451K	495K	714K	393K
Imputed Operating Lease Interest Expense	442K	491K	475K	1.2M	512K
Imputed Operating Lease Depreciation	-1.66K	-40.03K	19.54K	-481K	-119K
Stock-Based Comp., R&D Exp. (Total)	619K	947K	1.05M	1.45M	1.54M
Stock-Based Comp., G&A Exp. (Total)	1.38M	1.42M	1.79M	-	-
Stock-Based Comp., SG&A Exp. (Total)	-	-	-	3.41M	3.9M
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	2M	2.37M	2.84M	4.86M	5.44M

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Assets
Cash And Equivalents	71.82M	74.27M	71.06M	46.81M	75.66M
Short Term Investments	33.28M	1.01M	48.55M	30.18M	1.02M
Total Cash And Short Term Investments	105M	75.28M	120M	76.99M	76.68M
Accounts Receivable, Total	-	-	-	4.49M	11.72M
Other Receivables	-	-	-	-	-
Total Receivables	-	-	-	4.49M	11.72M
Inventory	-	-	1.23M	8.84M	13.9M
Prepaid Expenses	2.61M	2.79M	2.28M	2.44M	3.55M
Restricted Cash	-	182K	182K	-	-
Other Current Assets, Total	121K	24K	-	182K	-
Total Current Assets	108M	78.28M	123M	92.94M	106M
Gross Property Plant And Equipment	1.04M	649K	808K	1.52M	1.41M
Accumulated Depreciation	-136K	-170K	-188K	-61K	-80K
Net Property Plant And Equipment	908K	479K	620K	1.46M	1.33M
Other Long-Term Assets, Total	314K	283K	267K	82K	341K
Total Assets	109M	79.04M	124M	94.48M	108M
Liabilities
Accounts Payable, Total	1.67M	544K	1.52M	4M	3.88M
Accrued Expenses, Total	4.75M	3.99M	5.24M	8.75M	9.73M
Current Portion of Long-Term Debt	2.41M	9.8M	-	-	-
Current Portion of Leases	460K	476K	567K	176K	239K
Current Income Taxes Payable	40K	5K	49K	-	-
Other Current Liabilities	-	26K	42K	206K	1.02M
Total Current Liabilities	9.32M	14.85M	7.42M	13.13M	14.88M
Long-Term Debt	16.86M	7.35M	36.79M	38.81M	51.35M
Long-Term Leases	480K	-	7K	1.28M	1.1M
Other Non Current Liabilities	219K	367K	7.54M	4.03M	26.87M
Total Liabilities	26.88M	22.57M	51.76M	57.26M	94.2M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	3K	3K	3K	4K	5K
Additional Paid In Capital	244M	246M	299M	319M	380M
Retained Earnings	-162M	-190M	-227M	-281M	-366M
Comprehensive Income and Other	1K	-1K	32K	-1K	-
Total Common Equity	82.17M	56.47M	72.43M	37.22M	13.32M
Total Equity	82.17M	56.47M	72.43M	37.22M	13.32M
Total Liabilities And Equity	109M	79.04M	124M	94.48M	108M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	27.36M	27.37M	35.77M	36.05M	50.28M
ECS Total Common Shares Outstanding	27.33M	27.37M	34.26M	35.97M	50.1M
Book Value / Share	3.01	2.06	2.11	1.03	0.27
Tangible Book Value	82.17M	56.47M	72.43M	37.22M	13.32M
Tangible Book Value Per Share	3.01	2.06	2.11	1.03	0.27
Total Debt	20.21M	17.64M	37.37M	40.27M	52.69M
Net Debt	-84.89M	-57.64M	-82.25M	-36.72M	-23.98M
Debt Equivalent Oper. Leases	3.52M	3.61M	3.96M	5.71M	3.14M
Account Code - Inventory Valuation	3	-	5	5	5
Inventories - Raw Materials, Total	-	-	1.2M	4.26M	4.78M
Inventories - Work In Process, Total	-	-	29K	4.19M	7.01M
Inventories - Finished Goods, Total	-	-	-	396K	2.11M
Machinery, Total	134K	144K	147K	110K	127K
Full Time Employees	27	26	96	135	162
Part Time Employees	-	-	-	1	2

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Net Income	-32.21M	-28.03M	-36.84M	-54.81M	-85.15M
Depreciation & Amortization - CF	399K	438K	468K	626K	148K
Depreciation & Amortization, Total	399K	438K	468K	626K	148K
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	4.49M
(Gain) Loss From Sale Of Asset	-	-	-	11K	4K
(Gain) Loss on Sale of Investments - (CF)	-	-	-244K	-2.11M	-120K
Stock-Based Compensation (CF)	2M	2.37M	2.84M	4.86M	5.44M
Provision and Write-off of Bad Debts	-	-	-	-	57K
Other Operating Activities, Total	669K	678K	-451K	-1.49M	17.68M
Change In Accounts Receivable	-	-	-	-4.49M	-7.29M
Change In Inventories	-	-	-1.23M	-7.61M	-5.16M
Change In Accounts Payable	1.21M	-2.36M	1.77M	5.56M	592K
Change in Other Net Operating Assets	236K	-234K	-887K	221K	-1.23M
Cash from Operations	-27.69M	-27.15M	-34.58M	-59.24M	-70.54M
Capital Expenditure	-	-9K	-21K	-40K	-21K
Investment in Marketable and Equity Securities, Total	-33.46M	32.14M	-45.84M	20M	29.32M
Cash from Investing	-33.46M	32.13M	-45.86M	19.96M	29.3M
Long-Term Debt Issued, Total	-	-	47.3M	-	46.77M
Total Debt Issued	-	-	47.3M	-	46.77M
Long-Term Debt Repaid, Total	-	-2.5M	-17.5M	-	-50M
Total Debt Repaid	-	-2.5M	-17.5M	-	-50M
Issuance of Common Stock	61.31M	51K	47.98M	14.85M	54.23M
Repurchase of Common Stock	-164K	-81K	-54K	-	-166K
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-800K	-	-500K	-	19.24M
Cash from Financing	60.35M	-2.53M	77.23M	14.85M	70.08M
Net Change in Cash	-805K	2.45M	-3.21M	-24.43M	28.84M
Supplemental Items
Cash Interest Paid	1.99M	2.04M	2.56M	5.94M	6.04M
Cash Income Tax Paid (Refund)	226K	206K	190K	248K	211K
Levered Free Cash Flow	-16.01M	-17.11M	-19.81M	-40.4M	-46.89M
Unlevered Free Cash Flow	-14.39M	-15.5M	-17.75M	-35.32M	-46.64M
Change In Net Working Capital	-1.92M	2.15M	-1.56M	6.14M	11.73M
Net Debt Issued / Repaid	-	-2.5M	29.8M	-	-3.23M

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Profitability
Return on Assets	-20.08	-17.16	-22.24	-31.67	-40.08
Return on Total Capital	-21.41	-18.29	-24.58	-36.97	-56.42
Return On Equity %	-48.24	-40.44	-57.16	-99.97	-336.97
Return on Common Equity	-48.24	-40.44	-57.16	-99.97	-336.97
Margin Analysis
Gross Profit Margin %	-	-	-	71.96	68.73
SG&A Margin	-	-	-	392.62	213.72
EBITDA Margin %	-	-	-	-407.36	-178.23
EBITA Margin %	-	-	-	-407.53	-178.29
EBIT Margin %	-	-	-	-407.53	-178.29
Income From Continuing Operations Margin %	-	-	-	-403.22	-234.36
Net Income Margin %	-	-	-	-403.22	-234.36
Net Avail. For Common Margin %	-	-	-	-403.22	-234.36
Normalized Net Income Margin	-	-	-	-252.01	-118.75
Levered Free Cash Flow Margin	-	-	-	-297.22	-129.06
Unlevered Free Cash Flow Margin	-	-	-	-259.87	-128.39
Asset Turnover
Asset Turnover	-	-	-	0.12	0.36
Fixed Assets Turnover	-	-	-	13.08	26.06
Receivables Turnover (Average Receivables)	-	-	-	-	4.48
Inventory Turnover (Average Inventory)	-	-	-	0.76	1
Short Term Liquidity
Current Ratio	11.57	5.27	16.63	7.08	7.12
Quick Ratio	11.28	5.07	16.13	6.2	5.94
Operating Cash Flow to Current Liabilities	-2.97	-1.83	-4.66	-4.51	-4.74
Days Sales Outstanding (Average Receivables)	-	-	-	-	81.65
Days Outstanding Inventory (Average Inventory)	-	-	-	482.23	366.34
Average Days Payable Outstanding	-	-	-	88.19	87.85
Cash Conversion Cycle (Average Days)	-	-	-	-	360.14
Long Term Solvency
Total Debt/Equity	24.59	31.23	51.59	108.2	395.59
Total Debt / Total Capital	19.74	23.8	34.03	51.97	79.82
LT Debt/Equity	21.1	13.02	50.81	107.72	393.8
Long-Term Debt / Total Capital	16.94	9.92	33.52	51.74	79.46
Total Liabilities / Total Assets	24.65	28.55	41.68	60.61	87.61
EBIT / Interest Expense	-11.57	-10.03	-10.95	-6.82	-8.56
EBITDA / Interest Expense	-11.39	-9.84	-10.79	-6.73	-8.5
(EBITDA - Capex) / Interest Expense	-11.39	-9.84	-10.8	-6.73	-8.51
Total Debt / EBITDA	-0.69	-0.7	-1.05	-0.74	-0.82
Net Debt / EBITDA	2.88	2.27	2.31	0.67	0.37
Total Debt / (EBITDA - Capex)	-0.69	-0.7	-1.05	-0.74	-0.82
Net Debt / (EBITDA - Capex)	2.88	2.27	2.31	0.67	0.37
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	-	-	167.28
Gross Profit, 1 Yr. Growth %	-	-	-	-	155.27
EBITDA, 1 Yr. Growth %	-9.03	-13.75	40.06	53.3	16.95
EBITA, 1 Yr. Growth %	-9.03	-13.73	40.02	53.21	16.93
EBIT, 1 Yr. Growth %	-9.03	-13.73	40.02	53.21	16.93
Earnings From Cont. Operations, 1 Yr. Growth %	-2.39	-12.96	31.4	48.79	55.35
Net Income, 1 Yr. Growth %	-2.39	-12.96	31.4	48.79	55.35
Normalized Net Income, 1 Yr. Growth %	-2.39	-12.96	31.4	48.79	21.27
Diluted EPS Before Extra, 1 Yr. Growth %	-26.1	-21.82	26.74	9.55	34.39
Accounts Receivable, 1 Yr. Growth %	-	-	-	-	161.1
Inventory, 1 Yr. Growth %	-	-	-	618.7	57.27
Net Property, Plant and Equip., 1 Yr. Growth %	-30.47	-47.25	29.44	135.32	-8.91
Total Assets, 1 Yr. Growth %	41.1	-27.52	57.14	-23.93	13.8
Tangible Book Value, 1 Yr. Growth %	59.97	-31.28	28.27	-48.62	-64.21
Common Equity, 1 Yr. Growth %	59.97	-31.28	28.27	-48.62	-64.21
Cash From Operations, 1 Yr. Growth %	-9.03	-1.96	27.35	71.34	19.06
Capital Expenditures, 1 Yr. Growth %	-	-	133.33	90.48	-47.5
Levered Free Cash Flow, 1 Yr. Growth %	-16.37	6.85	15.98	103.9	16.58
Unlevered Free Cash Flow, 1 Yr. Growth %	-20.21	7.67	14.71	99.01	32.73
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	0.45	-11.42	9.91	46.53	33.9
EBITA, 2 Yr. CAGR %	0.45	-11.41	9.91	46.47	33.85
EBIT, 2 Yr. CAGR %	0.45	-11.41	9.91	46.47	33.85
Earnings From Cont. Operations, 2 Yr. CAGR %	4.59	-7.83	6.94	39.83	52.03
Net Income, 2 Yr. CAGR %	4.59	-7.83	6.94	39.83	52.03
Normalized Net Income, 2 Yr. CAGR %	4.59	-7.83	6.94	39.83	36.89
Diluted EPS Before Extra, 2 Yr. CAGR %	-9.1	-23.99	-0.46	17.83	21.34
Inventory, 2 Yr. CAGR %	-	-	-	-	236.2
Net Property, Plant and Equip., 2 Yr. CAGR %	-26.26	-39.44	-17.37	74.53	46.41
Total Assets, 2 Yr. CAGR %	7.85	1.13	6.72	9.33	-6.96
Tangible Book Value, 2 Yr. CAGR %	2.15	4.85	-6.11	-18.82	-57.12
Common Equity, 2 Yr. CAGR %	2.15	4.85	-6.11	-18.82	-57.12
Cash From Operations, 2 Yr. CAGR %	-1.96	-5.56	11.74	47.72	42.83
Capital Expenditures, 2 Yr. CAGR %	-	-	-	110.82	0
Levered Free Cash Flow, 2 Yr. CAGR %	-8.07	-5.47	11.24	53.78	53.83
Unlevered Free Cash Flow, 2 Yr. CAGR %	-10.7	-7.31	11.05	51.09	62.11
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	8.48	-4.52	3.19	22.8	35.92
EBITA, 3 Yr. CAGR %	8.5	-4.52	3.19	22.77	35.87
EBIT, 3 Yr. CAGR %	8.5	-4.52	3.19	22.77	35.87
Earnings From Cont. Operations, 3 Yr. CAGR %	10.59	-1.62	3.74	19.39	44.82
Net Income, 3 Yr. CAGR %	10.59	-1.62	3.74	19.39	44.82
Normalized Net Income, 3 Yr. CAGR %	10.59	-1.62	3.74	19.39	35.04
Diluted EPS Before Extra, 3 Yr. CAGR %	-45.36	-13.56	-9.86	2.77	23.11
Net Property, Plant and Equip., 3 Yr. CAGR %	-22.83	-34.05	-21.99	17.13	40.52
Total Assets, 3 Yr. CAGR %	-3.68	-5.53	17.13	-4.67	10.8
Tangible Book Value, 3 Yr. CAGR %	-8.14	-10.49	12.14	-23.2	-38.21
Common Equity, 3 Yr. CAGR %	-8.14	-10.49	12.14	-23.2	-38.21
Cash From Operations, 3 Yr. CAGR %	6.88	-1.96	4.34	28.85	37.47
Capital Expenditures, 3 Yr. CAGR %	-	-	-	-	32.64
Levered Free Cash Flow, 3 Yr. CAGR %	3.52	-3.34	1.15	36.14	40.01
Unlevered Free Cash Flow, 3 Yr. CAGR %	1.09	-4.96	-0.54	34.88	44.45
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	22.5	7.57	9.05	13.32	14.53
EBITA, 5 Yr. CAGR %	22.52	7.59	9.06	13.3	14.51
EBIT, 5 Yr. CAGR %	22.52	7.59	9.06	13.3	14.51
Earnings From Cont. Operations, 5 Yr. CAGR %	25.09	2.84	9.11	13.23	20.88
Net Income, 5 Yr. CAGR %	25.09	2.84	9.11	13.23	20.88
Normalized Net Income, 5 Yr. CAGR %	25.09	2.84	9.11	13.23	15.91
Diluted EPS Before Extra, 5 Yr. CAGR %	-37.53	-47.21	-30.55	-2.15	1.52
Net Property, Plant and Equip., 5 Yr. CAGR %	108.58	79.09	-20.69	-2.67	0.35
Total Assets, 5 Yr. CAGR %	126.09	14.72	0.35	0.15	6.83
Tangible Book Value, 5 Yr. CAGR %	35.13	8.78	-7.33	-13.92	-23.66
Common Equity, 5 Yr. CAGR %	35.13	8.78	-7.33	-13.92	-23.66
Cash From Operations, 5 Yr. CAGR %	23.5	11.93	8.8	15.51	18.3
Capital Expenditures, 5 Yr. CAGR %	-	0	-35.9	-	-
Levered Free Cash Flow, 5 Yr. CAGR %	-	6	6.54	16.35	19.62
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	12.21	4.96	14.37	20.92